TYRP1 and cutaneous melanoma: Using patient-derived models of cutaneous, acral, and uveal melanoma, we showed the relevance of TYRP1 surface expression as a target for CAR-T cell therapy for cutaneous melanoma and rare melanoma subtypes in patients with high TYRP1 overexpression.